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Abstract 
Background and Objective: The relationship between protoporphyrin IX (PpIX) 
photobleaching and cellular damage during aminolevulinic (ALA) photodynamic 
therapy (PDT) has been studied at the cellular level.  This study assessed the 
capability of a non-invasive fluorescence imaging system (Dyaderm, Biocam, 
Germany), to monitor changes in PpIX during real time methyl-aminolevulinate 
(MAL) PDT in dermatological lesions, and thus to act as a predictive tool in terms of 
observed clinical outcome post treatment.   
Materials and Methods: Patients attending Royal Cornwall Hospital (Truro, UK) for 
MAL-PDT to licensed lesions (actinic keratosis, Bowen’s disease and basal cell 
carcinoma) were monitored using the pre-validated non-invasive fluorescence 
imaging system.  Patients were imaged at three distinct time points: prior to the 
application of MAL, after the three hours of MAL application and immediately 
following light irradiation.  The fluorescence intensity of the images were analysed 
with image analysis software and the percentage change in fluorescence during light 
irradiation was related to the clinical outcome observed three months following 
treatment.  In total 100 patients underwent at least one session of MAL-PDT.   
Results: Significantly higher levels of change in PpIX fluorescence during light 
irradiation (P<0.005) were observed in lesions undergoing complete clearance at 
three months when compared to those patients who underwent partial or no 
clearance.  In contrast no significant difference (P>0.500) was observed in the total 
levels of PpIX recorded after MAL application in patients undergoing partial and 
complete clearance at three months. 
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Conclusions: PpIX photobleaching is indicative of the level of cellular damage PDT 
treatment will induce and therefore the clinical outcome expected within patients.  
This study indicated the potential of the commercially available fluorescence imaging 
system investigated to predict treatment success at the time of light irradiation and in 
the future it may be possible to employ it to individualise treatment parameters to 
improve dermatological PDT efficacy/outcome.    
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Introduction 
Non-melanoma skin cancers (NMSC) and associated precancerous lesions originate 
from non-melanocytic cell types within the epidermis and they are the most common 
malignancy in the Caucasian population (1).  They comprise more than one-third of 
all adult cancers within the U.S. (approximately 900,000 to 1,200,000 cases per 
year) (2) and the incidence is steadily increasing worldwide at a rate of 3 % – 8 % 
each year (3).  Although these cancers rarely metastasise, when left untreated they 
can cause extensive local damage to the skin and often disfigure the patient (due to 
their frequently prominent localisation in sun exposed areas).  The treatment of 
NMSC and the associated precancerous lesions therefore places a huge burden on 
health organisations.   
Photodynamic therapy (PDT) is a highly selective technique for the ablation of tumor 
tissue via the production of singlet oxygen and other reactive oxygen species (ROS) 
(4).  The photodynamic reactions generate the ROS providing that three critical 
components are present; a photosensitiser, light of the appropriate wavelength and 
oxygen (5) .  Topical PDT with the application of a prodrug (aminolevulinic acid, ALA 
or its methyl ester MAL) has found a niche in the treatment of dermatological 
conditions, especially in treating NMSC and other precancerous skin lesions (e.g. 
basal cell carcinoma (BCC), Bowen’s disease (BD) and actinic keratosis (AK)) which 
are all licensed indications in the UK (6).  High complete response rates are 
observed when treating these lesions with topical PDT and these are comparable to 
the standard treatment modalities of cryosurgery and surgical excision (7-10).  PDT 
has several advantages over standard treatment for NMSC and precancerous 
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lesions, particularly in terms of improved cosmetic outcome and the ability to easily 
treat large or multiple lesions (7-10).  
Endogenous protoporphyrin IX (PpIX) accumulates within cells following the topical 
application of ALA/MAL, which are converted enzymatically via the heme 
biosynthesis pathway (11,12).  PpIX accumulation occurs preferentially within tumor 
cells probably as a result of disruption of the stratum corneum and differences in 
enzyme activity within neoplastic and normal tissues (13).  The accumulated PpIX is 
activated via the application of red light (635 nm).  The majority of this energy 
dissipates as heat or fluorescence but occasionally a high energy triplet state is 
formed (12).  Interaction of the triplet state PpIX with molecular oxygen results in the 
production of singlet oxygen and other reactive oxygen species (ROS) which cause 
localised oxidative damage to the cells resulting in cell death via apoptosis or 
necrosis (14).  The characteristic optical properties of PpIX enable fluorescence 
diagnosis (FD) a technique that identifies and demarcates tumors and pre-cancers 
due to their preferential accumulation of PpIX in comparison with normal skin, 
thereby aiding diagnosis and surgical excision (15-18).  In addition FD equipment 
with appropriate validation/modification has the potential to follow the accumulation 
and destruction of the photosensitizer during real-time PDT.  
This study employed a commercially available imaging system (Dyaderm, Biocam, 
Germany) to monitor the changes in PpIX during real-time clinical dermatological 
MAL-PDT.  We have previously validated this system to ensure that changes in PpIX 
levels can be reproducibly followed during dermatological PDT (19).  Previous in vivo 
studies have indicated the positive correlation between PpIX photobleaching and 
cellular damage, indicating that greater photobleaching enhances the efficacy of the 
treatment (20-22).  This investigation considered the levels of PpIX photobleaching 
6 
 
and total PpIX fluorescence observed at the time of treatment with the clinical 
outcome at three months to determine whether this system had the potential to act 
as a predictor of treatment efficacy at the time of PDT treatment.   
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Materials and Methods 
Fluorescence imaging 
PpIX fluorescence was determined using a pre validated non-invasive imaging 
system (Dyaderm, Biocam, Germany) (19).  The system consisted of a Xenon flash 
light source that had a custom bandpass filter (370–440 nm) enabling alternation 
between white and blue light.  The light source had a low irradiance (3–5 mWcm-2) 
and a short exposure time to minimise ROS production during light irradiation.  
Previous investigations within our group have shown no significant alterations in 
PpIX fluorescence when sequential measurements were acquired (data not shown).  
Seven light pulses per second were delivered to the area of interest, and the 
returning light was collected by a 12-bit Sony charge coupled device (CCD) camera 
(exposure time 100 µs) which utilised a special Schott GG 455 longpass filter to 
exclude the excitation light.  The light source and CCD were combined in one 
adjustable arm coupled to a Pentium IV computer equipped with custom-made 
image capturing software (Dyaderm Pro v2, Biocam, Germany).  The red pixels of 
the CCD camera (spectral sensitivity of which at 630 nm was between 85% and 
90%) were used to generate a fluorescence image from the red spectrum 
fluorescence emitted from the excited PpIX.  In this way, a normal coloured image 
(from the white light) and a fluorescence image (from the blue light 370–440 nm) was 
simultaneously collected and processed by the system in real time.  
In addition to PpIX other fluorophores within the skin (e.g. lipopigments and flavins) 
were activated with the blue light and emitted light in the green spectrum.  This 
autofluorescence was also recorded by the camera.  The software computed a “PpIX 
filtered” image which corrected for the heterogeneity due to imperfections in the 
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excitation light and the natural curvature of the object imaged by combining the red 
and green fluorescence images.                
PDT treatment 
Patients attending the photodynamic therapy clinic in the Dermatology Department, 
Royal Cornwall Hospital, for routine dermatological PDT were provided with verbal 
and written information about the study prior to giving written consent before 
participating in this ethically approved (Cornwall and Plymouth Research Ethics 
Committee) fluorescence imaging study.  This study was therefore a non-
interventional, non-randomised, observational study.  All the lesions included were 
dermatological indications (AK, BD and BCC) for which MAL-PDT has been 
approved in the UK (6,23).  The majority of BCC and BD lesions were biopsied prior 
to referral for MAL-PDT treatment; in contrast AK lesions were referred at the 
Consultant Dermatologist’s discretion.  The BCC lesions monitored were all 
histologically considered to be superficial (less than 0.5 mm thick) in nature following 
clinical observation and biopsy.  Patients’ lesion(s) were imaged at both their first 
and second clinic visits if they received more than one PDT treatment.  One hundred 
patients were recruited and one lesion was monitored in each patient to limit 
statistical error.  There was an approximately equal split in terms of the three 
licensed lesions (37 AK, 29 BD and 34 BCC) and patient gender (56 Males and 44 
Females), with the age of the patient ranging from 45 – 96 years, with an average of 
77 years.  Our previous studies (data not shown) have indicated that the 
histologically distinct lesions behaved in a similar manner to MAL-PDT and therefore 
the data was analysed as a whole.  Patient gender and age have also been 
previously considered and these were not considered to contribute significantly to 
the changes in PpIX levels observed (data not shown).  The majority of patients (84 
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patients) received two treatments, nine days apart, to the individual lesions as per 
the NICE clinical guidelines (24) with the exception being superficial AK (16 patients) 
which only received (as recommended) a single PDT treatment.  The lesions were 
treated as per the standard clinical protocol, with overlying crust removed from the 
lesion prior to the application of a thin layer (1 mm thick with a border of 5 mm 
around the visible lesion) of the topical MAL cream (160 mg/g MAL, commercially 
known as Metvix®, Galderma, UK).  The lesion was then occluded from the light for 
a period of three hours.  After the allotted time the lesion was irradiated with a red 
light (Aktilite, Galderma, UK; 635 nm +/- 5 nm; 37 Jcm-2; 90 mWcm-2) which was 
positioned by a specialist nurse practitioner to be between 5 and 8 centimetres away 
from the lesion (in accordance with the NICE treatment guidelines (24)).   
The lesions were imaged at multiple time points during standard PDT treatment, 
specifically prior to the application of MAL, after the three hour MAL application 
period and immediately following light irradiation.  All images were taken in 
accordance with our previously derived standardised operating procedure which 
enabled reproducible images to be acquired by limiting the other factors potentially 
altering image acquisition (19).  To enable the identical region to be imaged the 
position of the camera was marked on the patients’ skin to enable replacement of the 
camera in the same place.  The fluorescence intensity within images (arbitrary units 
(AU)) were then analyzed at a consistent pixel position using ImageJ software to 
follow the changes in PpIX fluorescence within the lesion at the different points in the 
treatment.  When patients attended the clinic for a second treatment nine days later 
the images were acquired and analyzed in exactly the same manner.     
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Outcome at three months 
All patients attended an outpatient clinic three months after their last PDT treatment 
and the lesions were visually assessed by a Consultant Dermatologist who was 
blinded to the fluorescence imaging results.  The outcome reported was based on 
the initial assessment of the lesion entered in the notes, which included details of the 
lesion size and an image of the lesion prior to treatment.  If no clinical evidence of 
the tumour remained at three months then the lesions were considered to have 
undergone complete clinical clearance.  Lesions that were observed to have 
decreased in size but where (pre)cancerous cells clearly remained were reported to 
have undergone a partial clearance.  Lesions which remained unaltered following the 
one or two PDT treatments they had received were reported as no clearance. 
 
Data analysis   
The clinical outcomes recorded were related to the image analysis data in particular 
the total PpIX fluorescence recorded after the three hour MAL application and the 
percentage change in fluorescence intensity observed during light irradiation.  For 
each patient the total fluorescence after the three hour application of MAL was noted 
and the percentage change in fluorescence during light irradiation was calculated.  
The values were then allotted to the appropriate group (i.e. complete, partial or no 
clearance) and the median values of the outcome group calculated.  The analysis 
looked initially at the first and second MAL-PDT treatments separately and then the 
data were combined. 
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These non-parametric data were analysed using the Mann Whitney U test to 
compare the percentage changes in fluorescence during light irradiation or total PpIX 
fluorescence after the three hour MAL application observed in lesions undergoing 
complete, partial and no clearance.  Due to the low number of patients undergoing 
no clearance statistical analysis was only conducted between the complete and 
partial clearance groups.   
The z-test for two proportions was utilized to compare the percentage of patients 
within the complete and partial clearance groups that underwent a greater than 40%, 
50% and 60% fluorescence change in PpIX.  
It should be noted that this non-interventional, non-randomised, observational study 
of routine dermatological MAL-PDT practice was not powered in advance as no idea 
of the size of change in fluorescence intensity that might be observed during clinical 
light irradiation was previously known or indeed how this may be related (if at all) to 
the clinical outcome observed at three months.   
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Results 
Total PpIX fluorescence  
The median total PpIX fluorescence observed after the three hour MAL application 
were similar in all patients independent of the clinical outcome observed at three 
months (1st treatment: complete 132.94 au, partial 126.36 au and no response 
108.57 au; 2nd treatment: complete 104.91 au, partial 100.48 au and no response 
150 au)  (Figure 1).  When the grayscale fluorescence intensities after MAL 
application for complete responders (n = 72) were compared to the grayscale 
intensities for partial responders (n = 27) no significant differences were observed in 
lesions undergoing the first PDT treatment alone (P=0.529), nor the second PDT 
treatment alone (P=0.641), nor when the combination of the first and second 
treatments were analysed together (P=0.598) (Figure 1).        
 
Percentage change in fluorescence intensity during light irradiation 
Light irradiation resulted in a statistically significant decrease in the fluorescence 
intensity within the lesions which corresponded to the photobleaching of the lesion.   
Patients observed to undergo complete clinical clearance (n = 72) had statistically 
higher levels of change in PpIX fluorescence intensity during the first and second 
PDT treatments (P<0.005) in comparison to those patients who only underwent 
partial clearance (n = 27) (Figure 2).      
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Determination of an optimal percentage change in fluorescence 
The percentage of lesions undergoing a change in fluorescence intensity of greater 
than 40% during light irradiation was not noted to differ significantly between 
complete and partial responders.  In contrast fluorescence changes of 50% and 60% 
were significantly more likely within the complete responders group when compared 
with the partial responders group (P<0.01 and P<0.001 respectively, 90% power; 
Figure 3).  When a 70% change was analysed, the number of patients undergoing 
such a considerable change was considered too low for this to be a useful threshold.   
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Discussion  
MAL-PDT has become a successful treatment modality for the treatment of NMSC 
and skin pre-cancers (6,7,25).  The endogenous photosensitizer, PpIX, produced 
from the topical precursor MAL accumulates specifically within these lesions 
(12,13,26) and results in the production of singlet oxygen and other ROS when 
activated with red light.  Previous studies have shown a positive correlation between 
PpIX photobleaching and the induced cellular damage, indicating that greater PpIX 
photobleaching results in more efficacious PDT (20-22,27).  Therefore the potential 
exists to follow PpIX photobleaching and utilize it as a predictive tool in determining 
clinical outcome within the clinical setting.   
The characteristic fluorescent properties of PpIX enables fluorescence imaging 
which is normally employed to identify and demarcate lesions to aid their removal, 
but it also has the potential to follow PpIX accumulation and destruction during PDT 
(16).  Fluorescence spectroscopy is commonly used to follow changes in PpIX in 
vitro (28,29) and in animal models (22,30,31), however to date limited clinical data is 
available due to the poor reproducibility of results (32).  This study utilised a system 
which we had previously validated to follow PpIX changes during MAL-PDT (19) and 
related these to the observed clinical outcome after three months.   
Our findings indicated that the percentage change in fluorescence during light 
irradiation (which relates to PpIX photobleaching) (Figure 2) and not the total level of 
PpIX fluorescence prior to light irradiation (Figure 1) was associated with improved 
clinical outcome (observed at three months after treatment).  No significant 
difference was observed between complete, partial and non responders in terms of 
the total PpIX fluorescence detected prior to light irradiation (P>0.500).  In contrast 
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the percentage change in fluorescence in complete responders was statistically 
greater than in partial responders (P<0.005) for both the first and second PDT 
treatments.  Comparisons were only made between complete and partial responders 
in this study due to the lack of non-responders (only one patient showed no 
response to PDT treatment using our standard PDT treatment protocol).  The 
clearance rates (complete clearance 72% and partial clearance 27%) obtained are 
consistent with the literature which indicates that this standard MAL-PDT treatment 
regime is able to produce effective clearance in these approved dermatological 
indications (23,33).   
Figure 3 indicated that a significantly higher percentage of lesions undergoing 
complete clearance were observed to undergo changes in fluorescence of greater 
than 50% and 60% when compared with lesions undergoing a partial response 
(P<0.01 and P<0.001 respectively).  The purpose here was to try and predict 
treatment effectiveness at the time of PDT treatment in order to be able to alter 
treatment as appropriate (e.g. conduct another PDT treatment if not enough 
photobleaching was observed rather than waiting three months before retreating) 
and it appears that in this respect this may be possible with further investigation.  
The National Institute of Clinical Excellence (NICE) guidelines (24) recommend two 
PDT treatments seven days apart for licensed lesions treated with MAL-PDT (with 
the exception of superficial AK where one treatment is deemed sufficient).  The data 
in figure 3 suggests that a threshold percentage change of either 50% or 60% could 
be applied to determine whether a third and/or fourth treatment may be beneficial.  
Following this analysis, the authors would suggest a threshold of 60% should be 
considered for further investigation as this percentage demonstrated the greatest 
level of significance between the number of complete and partial responders 
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undergoing a change of this magnitude.  This highlights the potential of this system 
to individualise patient treatments with the aim of retreating lesions which did not 
undergo a ‘satisfactory’ change in fluorescence during the first one or two treatments 
conducted routinely.  This has the potential to reduce clinical time constraints 
(particularly for the Consultant) and reduce the economic burden of PDT treatment 
as patients may only need/require one subsequent PDT treatment rather than being 
referred for a further course of two PDT treatments. Further research would be 
required to determine whether implementing a PpIX photobleaching threshold level 
such as this could have this desired positive effect on dermatological PDT practice.    
It is important to note that within this study clinical outcome was determined at three 
months, as this is our standard clinical follow up period.  However the results may 
vary if outcome was determined at different time periods following treatment 
especially when considering long term follow ups (e.g. several years).  The literature 
commonly states that recurrence of the lesion can occur in regions previously 
considered clear several years following treatment (34).  This is most common in the 
initial years following treatment.   
The clinical outcome after treatment was determined by clinical evaluation only, not 
by histological analysis.  This was done to avoid another biopsy, preserve the good 
cosmesis achieved with PDT and is the normal method for determining outcome 
following PDT within our Department.  However, the reviewing Consultant compared 
the treated area with the previous explanations within the notes, particularly 
comparing size and visual appearance of the area.  The lesion was considered 
completely clear if no clinical signs were visible.   
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Monitoring PpIX photobleaching in vivo is known to be technically feasible 
(22,30,31,35) and has been demonstrated in this present work for the first time in 
patients undergoing dermatological MAL-PDT.  Despite this, the mechanistic 
relationships between photobleaching and the resulting photo-damage are not trivial 
(36).  The rate of photobleaching is thought to be dependent on the light fluence, 
photosensitiser concentration and the partial pressure of oxygen (pO2) within the 
tissues under investigation (36).  In terms of this study the light fluence was constant 
and therefore fluence and fluence rate were not a variable.  In contrast the pO2 will 
be of critical importance to the efficacy of PDT as it is related to the level of singlet 
oxygen produced within the localised area (37).  The oxygenation of the tissue is 
known to determine the photobleaching rate (36) and therefore the initial value of 
pO2 within the tissue needs to be considered.  During light delivery the oxygen level 
will be reduced due to photochemical consumption, and due to the variability in initial 
tissue pO2, in some instances photobleaching may switch from oxygen-dependent to 
oxygen-independent mechanisms (38).    A link between oxygen-independent 
photobleaching and photochemical damage is yet to be determined however.  This 
indicates that photobleaching alone may not be suitable to determine clinical 
outcome in patients undergoing MAL-PDT as the fluorescence measurements alone 
do not consider oxygen independent photobleaching, which due to the heterogeneity 
of microvasculature in skin is certainly plausible.  Although in the skin a proportion of 
the oxygenation comes from the atmosphere rather than the vasculature (39).      
Previous literature has indicated that PpIX photobleaching differs at various PpIX 
concentrations in vitro, with higher PpIX concentrations relating to lower PpIX 
photobleaching (20,40).  This is proposed to occur due to the localisation of PpIX at 
secondary sites (which protect PpIX from singlet oxygen or make it less photoactive) 
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following the saturation of the primary binding sites.  The clinical relevance of this is 
currently not known, and in this study with the sample size investigated no significant 
difference was observed in the total PpIX fluorescence observed prior to light 
irradiation in the complete and partial responders (P>0.500).   
The clinical data presented here are consistent with the literature in terms of the 
positive correlation previously observed between PpIX photobleaching and cellular 
damage (20-22,41).  Importantly this study looks at percentage change in 
fluorescence rather than the raw data generated from the non-invasive imaging 
system utilized which would be device specific and therefore the thresholds 
postulated here with investigation could be utilized by other clinical investigators with 
other fluorescence monitoring devices.      
This study has indicated the potential of a commercially available fluorescence 
imaging system to follow changes in PpIX fluorescence non-invasively in real time 
during routine dermatological practice and also indicates that it may be possible to 
use PpIX photobleaching during light irradiation to give an indication of likely 
treatment outcome at three month follow-up whilst PDT is still in progress.   
Disclosure: “I certify that I have no affiliation with or financial involvement in any 
organization or entity with a direct financial interest in the subject matter or materials 
discussed in the manuscript (e.g., employment, consultancies, stock ownership, 
honoraria) except as discussed in an attachment." 
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Figures 
Figure 1 – Box and whisker plot illustrating the spread of the total PpIX fluorescence 
observed after three hours of MAL application for patients undergoing complete or 
partial clearance after the first and second MAL-PDT treatments.  The central line of 
the box represents the median value of the group, the edges are the corresponding 
inter-quartile values, the whiskers represent the 10th and 90th percentiles of the data 
and the dots represent outliers.     
Figure 2 – Box and whisker plot indicating the percentage change in PpIX 
fluorescence during light irradiation for complete and partial responders to MAL-PDT.  
* represents statistical significance at P<0.005 between the complete reponders and 
corresponding partially responding group.  The central line of the box represents the 
median value of the group, the edges are the corresponding inter-quartile values, the 
whiskers represent the 10th and 90th percentiles of the data and the dots represent 
outliers. 
Figure 3 – Bar chart indicating the percentage of complete, partial and non-
responders that underwent a greater than 40, 50 or 60% change in fluorescence 
during light irradiation in at least one of the MAL-PDT treatments.   
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